Avanir Pharmaceuticals (AVNR) PT Lifted to $17 at Piper Jaffray on Positive Phase II Results
Tweet Send to a Friend
Piper Jaffray analysts Charles Duncan and Roy Buchanan lifted their price target on Avanir Pharmaceuticals (NASDAQ: AVNR) to $17.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
